DOPA effects on motility in mice; potentiation by MK 485 and dexchlorpheniramine.
D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001812:Blood-Brain Barrier; D001921:Brain / Q000378:metabolism; D002744:Chlorpheniramine / Q000494:pharmacology*; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D004357:Drug Synergism; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology*; D006948:Hyperkinesis / Q000139:chemically induced; D051379:Mice; D009043:Motor Activity / Q000187:drug effects*; D009638:Norepinephrine / Q000378:metabolism; D011725:Pyridines / Q000494:pharmacology*; D012701:Serotonin / Q000378:metabolism; D013237:Stereoisomerism
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D006834:Hydrazines; D011725:Pyridines; D012701:Serotonin; D002744:Chlorpheniramine; D004295:Dihydroxyphenylalanine; D004298:Dopamine; D009638:Norepinephrine